Peptides DB
Research-centric peptide and protocol reference hub
Study 26 of 29Semaglutide literatureJournal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology · Observational2026

Comparison of lifestyle, surgery, and semaglutide for weight management in endometrial cancer: a prospective observational study.

In patients with endometrial cancer, sleeve gastrectomy leads to greater short-term weight loss, but a structured lifestyle program may be more effective for long-term weight maintenance and metabolic health.

Read at Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and GynaecologyAdd to compare

Where it sits

this study against the rest of the semaglutide corpus
7
Preclinical
16
Observational · this one
0
Open-label
2
Randomised
4
Reviews

Summary and findings

This study compared sleeve gastrectomy, semaglutide therapy, and the DEAR weight management program in 53 patients with endometrial cancer. The primary outcome was weight loss and metabolic improvement over two years. Results indicated that sleeve gastrectomy led to the largest BMI reduction at one year, while the DEAR program showed better weight maintenance and metabolic stability at two years.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
sleeve gastrectomy group had a BMI reduction difference of 4.04 kg/m² compared to the semaglutide group, p < 0.052026

Abstract

The authors’ words, as Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology supplied them

<h4>Background</h4>To compare sleeve gastrectomy, semaglutide therapy, and the Diet, Exercise, Accompany and Refresh (DEAR) weight management programme for weight control, metabolic improvement, and oncological outcomes in patients with endometrial cancer receiving fertility-sparing treatment.<h4>Methods</h4>In this prospective observational study, 53 patients received sleeve gastrectomy (<i>n</i> = 10), semaglutide therapy (<i>n</i> = 23), or the DEAR programme (<i>n</i> = 20) after multidisciplinary assessment and shared decision-making. Anthropometric and metabolic measures and tumour response were assessed over two years.<h4>Results</h4>At 1 year, all groups lost weight; the sleeve gastrectomy group had the largest body mass index reduction compared with the semaglutide group (difference = 4.04 kg/m<sup>2</sup>, <i>p</i> < 0.05) and the DEAR group (difference = 2.12 kg/m<sup>2</sup>, <i>p</i> < 0.05). By 2 years, weight regain was less frequent in the DEAR group (14.3%) than in the semaglutide (55.6%) and sleeve gastrectomy (66.7%) groups (<i>p</i> = 0.037). The DEAR group showed more stable metabolic improvements and the highest complete tumour remission rate (85.0%), followed by the semaglutide group (73.9%) and the sleeve gastrectomy group (60.0%).<h4>Conclusion</h4>Sleeve gastrectomy produced rapid short-term weight loss, whereas the DEAR programme showed better medium-term weight maintenance, metabolic stability, and tumour response. Integrated lifestyle support may be a useful medium-term strategy for patients seeking fertility preservation.

Elsewhere in the Semaglutide corpus

DCagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.The lancet. Diabetes & endocrinology · 2026DEfficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.The lancet. Diabetes & endocrinology · 2026D1-year outcomes of semaglutide, tirzepatide, and sleeve gastrectomy in obesity in type 2 diabetes: a retrospective cohort study.The lancet. Diabetes & endocrinology · 2026BGLP-1 and GIP receptor agonism does not directly drive skeletal muscle atrophy or impair myogenesis in primary human myotubesbiorxiv-preprint · 2026 · Semaglutide reduced glycolytic and total ATP production rates, exact values not reported.HumanBReal-World Study of Cardiac Remodeling on Semaglutide and Tirzepatide Therapy Using Longitudinal Echocardiographybiorxiv-preprint · 2026 · LV mass decreased from 198.4 ± 69.6 g to 176.6 ± 66.0 g in super-responders, p < 0.001.HumanBExenatide Is Associated with Superior Gastrointestinal Motility Slowing Among GLP-1 Receptor Agonistsbiorxiv-preprint · 2020 · n=20 · Prevalence of anti-constipation prescriptions increased from 11.09% to 18.62% in the exenatide cohort over 12 months, p=6.75×10⁻⁴.Human